Key Points
- Director Robert Williamson III purchased 9,498 shares at an average price of $2.10 on Nov. 12, a ~2,595% increase in his position, bringing his total holding to 9,864 shares for a transaction value of about $19,946.
- Perspective shares traded near $2.08 with a 12-month range of $1.60–$8.93, while the company reported a recent quarterly EPS of -$0.35 (missing estimates) and extremely negative net margins despite strong liquidity metrics (current and quick ratios ~15.09).
- Analysts are broadly bullish (mix of Strong Buy/Buy ratings) with an average price target of about $11.89, and institutional investors (including Vanguard and Affinity) now own roughly 54.7% of the stock after recent stake increases.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) Director Robert Williamson III acquired 9,498 shares of the company's stock in a transaction on Wednesday, November 12th. The stock was purchased at an average cost of $2.10 per share, for a total transaction of $19,945.80. Following the completion of the transaction, the director owned 9,864 shares in the company, valued at approximately $20,714.40. The trade was a 2,595.08% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.
Perspective Therapeutics Trading Up 0.5%
Shares of Perspective Therapeutics stock traded up $0.01 during trading on Friday, hitting $2.08. 4,988,714 shares of the stock were exchanged, compared to its average volume of 1,037,764. The company has a debt-to-equity ratio of 0.01, a current ratio of 15.09 and a quick ratio of 15.09. The firm's 50-day moving average price is $3.24 and its 200 day moving average price is $3.31. Perspective Therapeutics, Inc. has a 12-month low of $1.60 and a 12-month high of $8.93.
Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.02). The business had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.21 million. Perspective Therapeutics had a negative return on equity of 33.37% and a negative net margin of 7,688.50%. Equities analysts anticipate that Perspective Therapeutics, Inc. will post -0.88 EPS for the current year.
Hedge Funds Weigh In On Perspective Therapeutics
Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Perspective Therapeutics by 5.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company's stock worth $11,792,000 after acquiring an additional 163,532 shares in the last quarter. Affinity Asset Advisors LLC raised its holdings in Perspective Therapeutics by 71.1% during the first quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company's stock worth $4,738,000 after purchasing an additional 924,196 shares during the last quarter. Nicholson Wealth Management Group LLC boosted its position in Perspective Therapeutics by 0.3% during the second quarter. Nicholson Wealth Management Group LLC now owns 1,614,283 shares of the company's stock worth $5,553,000 after purchasing an additional 5,000 shares in the last quarter. Geode Capital Management LLC grew its holdings in Perspective Therapeutics by 15.8% in the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company's stock valued at $4,758,000 after purchasing an additional 188,887 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in Perspective Therapeutics in the first quarter valued at $2,647,000. Hedge funds and other institutional investors own 54.66% of the company's stock.
Analyst Ratings Changes
Several analysts have commented on CATX shares. Wedbush reaffirmed an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Perspective Therapeutics in a report on Friday, October 3rd. Finally, BTIG Research started coverage on Perspective Therapeutics in a research note on Friday, October 10th. They set a "buy" rating and a $14.00 price target for the company. Four analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $11.89.
Check Out Our Latest Report on CATX
Perspective Therapeutics Company Profile
(
Get Free Report)
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
